GRAL Stock Chart & Stats
$825.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$582.21 - $1,997.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$53.10B
Enterprise ValueN/A
Total Cash (Recent Filing)$823.11M
Total Debt (Recent Filing)$51.03M
Price to Earnings (P/E)―
Beta2.55
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding42,916,590
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.22
Price to Sales (P/S)21.37
P/FCF Ratio-10.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial Volume GrowthQ1 unit and revenue growth demonstrate accelerating market adoption and distribution reach. Durable provider integrations and a rising prescriber base imply recurring demand and scaling potential, which supports long‑term revenue durability and increasing competitive advantage as fixed costs are absorbed.
Improving Unit EconomicsMaterial improvement in adjusted gross profit and adjusted EBITDA shows the business is leveraging fixed costs and reducing reprocessing expense. Sustained unit‑economics improvement is a structural lever to convert volume growth into durable margins and reduce future financing needs.
Regulatory Progress And Evidence BasePMA acceptance and very large supporting datasets provide regulatory validation and clinical credibility. A robust evidence base materially strengthens long‑term adoption by clinicians and payers, lowering structural approval and reimbursement barriers versus rivals with weaker data.
Bears Say
Negative Gross Margins & Cash BurnPersistently negative gross margin and ~-$291M TTM cash burn mean the business is not yet self‑funding. Continued losses erode equity and require financing unless durable margin expansion and consistent positive free cash flow are achieved within the medium term, risking dilution or constrained investment.
NHS‑Galleri Primary Endpoint MissA high‑profile primary endpoint miss creates lasting credibility and perception challenges with providers, payers, and employers. Even with forthcoming ASCO data, restoring confidence and converting evidence into broader clinical adoption and coverage decisions will take multiple quarters and focused education.
Regulatory And Reimbursement Timing UncertaintyUnclear FDA timeline and CMS coverage create structural execution risk: reimbursement timing and regulatory cadence directly affect scale economics, salesforce ROI, and pricing strategies. Delays or adverse timing could materially defer revenue scaling and margin sustainability over many quarters.
GRAL FAQ
What was Grail Inc’s price range in the past 12 months?
Grail Inc lowest stock price was $582.21 and its highest was $1997.99 in the past 12 months.
What is Grail Inc’s market cap?
Grail Inc’s market cap is $53.10B.
When is Grail Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Grail Inc’s earnings last quarter?
Currently, no data Available
Is Grail Inc overvalued?
According to Wall Street analysts Grail Inc’s price is currently Undervalued.
Does Grail Inc pay dividends?
Grail Inc does not currently pay dividends.
What is Grail Inc’s EPS estimate?
Grail Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grail Inc have?
Grail Inc has 42,916,590 shares outstanding.
What happened to Grail Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Grail Inc?
Currently, no hedge funds are holding shares in MX:GRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GRAIL Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MX:GRAL Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
72.11%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.55%
Trailing 12-Months
Company Description
Grail Inc
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.